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S164 Oral Presentationsdiscovery approach identical to that we employed for elafin, we first
analyzed plasma pooled from ten patients with and ten without GI
GVHD. We identified 164 candidate proteins that were increased
at least 1.5 fold, and two lead candidates, REG3a and CEACAM1,
were preferentially expressed in the GI tract and measurable by
ELISA. We then validated these two candidates in plasma from 570
BMT patients: 113 GI GVHD; 223 no GVHD; 52 non-GVHD
(e.g. infectious) enteritis; and 182 skin onlyGVHD.Groups were bal-
anced for age, myeloablative conditioning and sample collection. Un-
related and HLA-mismatched donors were over-represented in the
GVHD patient groups. REG3a levels were two to four fold higher
in the GI GVHD group compared to all others (mean6SEM in ng/
ml: 245640, 6468, 74618, 112622, respectively, p\ 0.004). The
area under the curve (AUC) of the receiver operating characteristic
(ROC) curve of GI GVHD with respect to non-GVHD enteritis
was 0.75 (95%CI, 0.66-0.82). Similar differences between patient
groups were seen with CEACAM1, but including CEACAM1 in
a composite ROC curve of both markers performed no better than
REG3a alone (AUC 5 0.75). Thus, subsequent analyses were per-
formed on REG3a. We divided patients with GI symptoms (n 5
165) into two equal groups based on the median concentration of
REG3a: low (\ 65 ng/ml, n 5 83) and high ($ 65 ng/ml, n 5 82).
The REG3ahigh group developed more severe GVHD, had higher
1year non-relapse mortality (NRM), and lower 1 year overall survival
(OS), than the REG3alow group (Table 1). KRT18 has previously
been reported as a marker for liver/GI GVHD (Blood, 114:702-
708); we measured its levels on the same patient samples and found
that while levels were significantly different in GI GVHD than in
non-GVHD enteritis (p5 0.01), they were not significantly different
between GI and Skin GVHD (p 5 0.5), and they did not correlate
with GVHD severity, NRM or OS (Table 1). We have identified
and validatedREG3a, aC-type lectinwhoseGI expression is increased
in response to inflammatory stimuli such as bacteria, mucosal damage
or inflammatory bowel disease (Science, 313:1126-1130), as a diagnos-
tic biomarker of GI GVHD with significant prognostic value.34
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Introduction: Relapse is a major cause of hematopoietic cell trans-
plant (HCT) failure. Successful recovery of immunity against leuke-
mia treated with HCT (GVL immunity) is important in preventing
relapse. Thus, assays measuring GVL immunity could identify pa-
tients at risk of disease relapse. There is an association between re-
constitution of GVL immunity and herpesvirus specific immunity
(Parkman et al, BBMT 2006). Here we evaluated multiple assays
of anti-EBV/VZV/HHV6 immunity for their suitability to serve as
surrogates for GVL immunity and global antimicrobial immunity.
Patients &Methods:On day 56 post-transplant, we studied 46 allo-
HCT recipients for AML, who did not develop GVHD by day 56.
Blood mononuclear cells were stimulated with viral lysate from
EBV,HHV6 orVZV, or overlappingEBNA3, LMP112 orU54 pep-
tides, incubated overnight, stained for CD3, CD4, CD8, IFNg,
TNFa and IL2 and analyzed by flow cytometry. Patients were
followed for relapse and definite (microbiologically documented)Table 1. REG3a at onset of GI symptoms correlates with maximum
Maximum GVHD Grade
0 II-IV p-val
Low REG3a (%,95%CI) 45% (35%,55%) 55% (45%,65%) <0.0
High REG3a (%,95%CI) 17% (11%,27%) 83% (73%,89%)
Low KRT18 (%,95%CI) 34% (24%,45%) 66% (55%,76%) 0.5
High KRT18 (%,95%CI) 29% (20%,40%) 71% (60%,80%)infections. Absolute counts of each specific T cell subset were com-
pared between patients who did vs. did not relapse (or did vs. did
not develop at least one infection between day 56 and 180) using
Mann-Whitney test. Subsets with lowest p values were combined
into a scoring system, where for each subset, a score of 1 was assigned
to patients that had absolute counts above a cutoff, determined as the
mean between the highest value in patients who relapsed or developed
at least one infection and the nearest highest value.
Results:The following subset counts showed the highest association
with relapse: VZV specific CD4T cells producing IFNg, EBV lysate
specific CD8T cells producing IFNg and IL2, BZLF1 specific CD4
T cells producing IL2 with IFNg or TNFa, and BZLF1 specific T
cells producing TNFa and IL2. When the scores of these 5 subsets
were combined, a score of\1 was 100% sensitive and 78% specific
for relapse. The following subsets showed the highest association
with infections: U54 specific CD8 T cells producing TNFa,
EBNA3 specific CD4 T cells producing TNFa and IL2, and EBV
lysate specific CD8 T cells producing IFNg, TNFa and IL2. The
score of\ 1 was 100% sensitive and 36% specific for developing
at least one infection between day 56 and 180.
Conclusion: Herpesvirus specific T cell counts can serve as surro-
gates of both GVL immunity and global antimicrobial immunity.
They are highly sensitive but only moderately specific for relapse
and infections.35
CHARACTERIZING BIDIRECTIONAL INTERACTIONS BETWEEN THE
INTESTINAL FLORA AND GRAFT-VERSUS-HOST DISEASE
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Our immune system interacts dynamically with our microbial
flora. Perturbing this balance can lead to pathological inflammation.
Prior animal and clinical studies of allogeneic hematopoietic stem
cell transplantation (HSCT) suggest that variations in gut flora can
predispose or protect against graft-versus-host disease (GVHD).
Gut decontamination as GVHD prophylaxis, however, gave mixed
results, and our knowledge of the gut microbiota was limited to
the 20-30% of species that can be cultured. Novel methodology, in-
cluding 16s ribosomal DNA sequencing, allows more complete
characterization of the gut flora. We thus revisited whether manip-
ulation of gut flora can minimize GVHD.
We used a MHC-disparate B10BR/B6 mouse model for allo-
HSCT and found that GVHD leads to changes in gut flora, particu-
larly in the distal ileum. Shifts in representationbybacterial families re-
sult in a nearly complete takeover by Lactobacillaceae and loss of
several familiesofFirmicutes (Table).These changes are readily repro-
ducible, includingwith individually-housedmice. This pattern of flora
associated with GVHD was distinct from patterns found in control
groups: HSCT recipients without GVHD, mice with dextran sulfate
sodium-induced colitis, and mice treated with osmotic laxatives.
Potential mechanisms behind this characteristic GVHD-associ-
ated flora are continuing to be explored, but thus far do not appear
to be due to changes in numbers of Paneth cells, expression of
IL22 or the antimicrobial molecule Reg3g, or luminal levels of
IgA. Interestingly, the bacterial density in the ileum, quantified by
copies of 16s rDNA, is similar in mice with or without GVHD after
HSCT, and is twice that of untreated mice.
We then performed experiments evaluating flora manipulation
prior to HSCT. We found that ampicillin treatment followed by
a 2 week recovery results in complete loss of Lactobacillaceae andGVHD grade, 1 year NRM and 1 year OS
ue 1 year NRM p-value 1 year OS p-value
01 24% (15%,35%) <0.001 68% (58%,79%) 0.001
49% (38%,60%) 43% (33%,56%)
4 39% (29%,51%) 0.9 57% (47%,69%) 0.22
33% (23%,44%) 54% (44%,66%)
